Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Vasculitis

Vasculitis

Vasculitis refers to a group of disorders characterized by inflammation of blood vessels.
This can lead to narrowing, weakening, or damage to the vessel walls, impairing blood flow and causing organ and tissue damage.
Vasculitis can affect arteries, veins, and capillaries throughout the body, and may be caused by autoimmune disorders, infections, or other underlying conditions.
Symptons can vary widely depending on the type and location of vasculitis, but may include fever, fatigue, pain, and organ dysfunction.
Accurate diagnosis and effective treatment are crucial for managing vasculitis and preventing long-tern complications.
Researchers can use PubCompare.ai to optimize their vasculiits research protocols, easily identifying the best approaches based on a comprhensive analysis of published literature, preprints, and patent data.

Most cited protocols related to «Vasculitis»

1
Evaluating Novel SLE Classification
To assess the performance of the new classification rule, we obtained detailed data regarding a new set of 690 additional patients. Sites were again asked to submit information on patients diagnosed with SLE, and on an approximately equal number of controls with the following diagnoses: rheumatoid arthritis, undifferentiated connective tissue disease, primary antiphospholipid antibody syndrome, vasculitis, chronic cutaneous lupus, scleroderma, Sjögren syndrome, myositis, psoriasis, fibromyalgia, alopecia areata and sarcoidosis. These data were collected on standardized case report forms and sent to the coordinating site. Information included a demographics summary, a clinical scenario, specification of ACR criteria that were met and not met, specification of SLICC criteria met and not met, auto-antibody titers and complement titers.
In addition, serum from each patient was sent to the coordinating site and analyzed at the Rheumatology Diagnostic Laboratory (Los Angeles, CA) for anti-dsDNA by ELISA, Crithidia and Farr assays, anti-Smith antibody and complement C3 and C4 levels. A second set of blood samples were tested for antiphospholipid antibodies (lupus anticoagulant, ELISA assay for IgG, IgM and IgA isotypes of anticardiolipin antibodies and anti-beta2 glycoprotein1 antibodies) at the laboratory of Joan Merrill, M.D. (Oklahoma Medical Research Foundation). Direct Coombs was done at each center's own laboratory or at Quest Diagnostics. A short description of each patient (“patient scenario”) was generated containing the submitted information and the updated auto-antibody and complement profiles.
Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., Sturfelt G., Ramsey-Goldman R., Bae S.C., Hanly J.G., Sanchez-Guerrero J., Clarke A., Aranow C., Manzi S., Urowitz M., Gladman D., Kalunian K., Costner M., Werth V.P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M.A., Jacobsen S., Buyon J.P., Maddison P., Dooley M.A., van Vollenhoven R.F., Ginzler E., Stoll T., Peschken C., Jorizzo J.L., Callen J.P., Lim S.S., Fessler B.J., Inanc M., Kamen D.L., Rahman A., Steinsson K., Franks AG J.r., Sigler L., Hameed S., Fang H., Pham N., Brey R., Weisman M.H., McGwin G J.r, & Magder L.S. (2012). Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis and rheumatism, 64(8), 2677-2686.
Publication 2012
Alopecia Anti-Antibodies Antibodies, Anti-Idiotypic Antiphospholipid Antibodies Antiphospholipid Syndrome Biological Assay BLOOD Complement 3 Crithidia Dermatosclerosis Diagnosis Direct Coombs Test DNA, Double-Stranded Enzyme-Linked Immunosorbent Assay Fibromyalgia Immunoglobulin Isotypes Immunoglobulins Lupus Coagulation Inhibitor Lupus Erythematosus, Chronic Cutaneous Myositis Patients Psoriasis Radioimmunoprecipitation Assay Rheumatoid Arthritis Sarcoidosis Serum Sjogren's Syndrome Undifferentiated Connective Tissue Diseases Vasculitis
2
Comprehensive SLE Cohort Protocol
Each participating center was asked to submit data on 10 to 12 consecutive patients with a clinical diagnosis of SLE and 12 to 15 controls. The controls were to consist of consecutively seen patients with one of the following diagnoses: rheumatoid arthritis, myositis, chronic cutaneous lupus, undifferentiated connective tissue disease, vasculitis, primary antiphospholipid antibody syndrome, scleroderma, fibromyalgia, Sjögren syndrome, rosacea, psoriasis, sarcoidosis and juvenile idiopathic arthritis. Because it was recognized that important control groups , including chronic cutaneous lupus, which had not necessarily been part of previous efforts, needed to be represented, cases were also contributed by a number of dermatologists.
Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., Sturfelt G., Ramsey-Goldman R., Bae S.C., Hanly J.G., Sanchez-Guerrero J., Clarke A., Aranow C., Manzi S., Urowitz M., Gladman D., Kalunian K., Costner M., Werth V.P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M.A., Jacobsen S., Buyon J.P., Maddison P., Dooley M.A., van Vollenhoven R.F., Ginzler E., Stoll T., Peschken C., Jorizzo J.L., Callen J.P., Lim S.S., Fessler B.J., Inanc M., Kamen D.L., Rahman A., Steinsson K., Franks AG J.r., Sigler L., Hameed S., Fang H., Pham N., Brey R., Weisman M.H., McGwin G J.r, & Magder L.S. (2012). Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis and rheumatism, 64(8), 2677-2686.
Publication 2012
Antiphospholipid Syndrome Dermatologist Dermatosclerosis Diagnosis Fibromyalgia Juvenile Arthritis Lupus Erythematosus, Chronic Cutaneous Myositis Patients Psoriasis Rheumatoid Arthritis Rosacea Sarcoidosis Sjogren's Syndrome Undifferentiated Connective Tissue Diseases Vasculitis Vision
3
Quantifying Dengue Virus Incubation Periods
Relevant literature was collected by searching the PubMed, Ovid, and the Armed Forces Pest Management Board Literature Retrieval System databases using combinations of search terms including Aedes aegypti, Stegomyia fasciata (previous name for Ae. aegypti), Aedes albopictus, dengue, experiment, import, incubation, transmission, temperature, and travel. We did not restrict the search based on time of publication or language. Further material was found by reviewing references from identified papers.
The moment when a mosquito becomes infectious is not directly observable, so observations of the EIP are restricted to the window between exposure(s) and transmission experiment(s), defined by a minimum and maximum EIP. For example, if a mosquito is shown to be infectious 10 days after exposure, the EIP must be between 0 and 10 days. If the same mosquito is tested at day 5 and does not transmit DENV at that time, the EIP is between 5 and 10 days. For each observation, the maximum EIP was defined as the time from the first infectious blood meal to the first successful transmission of DENV. If transmissibility was tested and never successful, the maximum EIP is unknown. The minimum EIP was the time from the last infectious blood meal to the last negative transmission experiment or zero if there were no negative transmission experiments.
Acceptable transmission assays involved the confirmation of transmission to a naïve individual as evidenced by the onset of dengue or by laboratory evidence of infection such as hemagglutination inhibition or plaque reduction neutralization assays. Because dengue is used as an indicator, there may be some false-negative tests resulting from asymptomatic infections. We initially assume that all negative tests are truly negative and revisit this assumption later.
Observations of the EIP were limited to those in which Ae. aegypti or Ae. albopictus were fed on viremic humans or non-human primates. We also excluded observations in which infection of the mosquito was attained by injection or by feeding on animal blood or artificial media seeded with DENV, as these may not realistically mimic natural transmission.
Temperature data were recorded for each EIP observation when available. For observations with no temperature data, we obtained temperature data for the location of the study at the time of year when the study was undertaken from the Climate Research Unit 30-year mean climatology dataset (CL 2.0) [27] . The available temperature data was used to calculate a spatially and seasonally matched mean temperature for each observation.
The IIP analysis was restricted to events in which humans became sick after being experimentally infected by Ae. aegypti or Ae. albopictus or after being naturally exposed to DENV within a defined period of time by travelling into or out of an area with ongoing DENV transmission. In this case, the end event, the onset of symptoms, was always observed, but the exact exposure time is only known in the case of experimental infections. In those cases, the IIP was directly observed and therefore uncensored. In other cases, the maximum and minimum IIP were defined as the time from the first and last potential exposures, respectively, to the onset of illness. For example, a traveler who became sick 3 days after returning from a 10-day trip may have been exposed at any time during the trip, so the IIP must be between 3 and 13 days.
Further ancillary data collected for the analyses included the serotype of virus when known. The data is available in Text S1.
Chan M, & Johansson M.A. (2012). The Incubation Periods of Dengue Viruses. PLoS ONE, 7(11), e50972.
Full text: Click here
Publication 2012
Aedes Animals Asymptomatic Infections Biological Assay BLOOD Climate Culicidae Dengue Fever Dental Plaque Hemagglutination Inhibition Tests Homo sapiens Infection Laboratory Infection Military Personnel Primates Transmission, Communicable Disease TRIP10 protein, human Vasculitis Viremia Virus
4
Rituximab vs. Standard Therapy for ANCA-Associated Vasculitis
The first and last authors designed the trial in collaboration with the clinical development team at the Immune Tolerance Network and clinical investigators of the RAVE research group. The site investigators gathered the data, and the data were analyzed by the RAVE data committee, which consisted of the two coprincipal investigators and representatives of the Immune Tolerance Network, the National Institute of Allergy and Infectious Diseases, and the coordinating center (Rho). The data committee did not include representatives of either Genentech or Biogen Idec, which provided funding and medications for the study. The manuscript was drafted and written by the first and last authors, with input as appropriate from members of the RAVE data committee and the clinical investigators. The RAVE data committee made the decision to submit the manuscript for publication, and the first and last authors vouch for the accuracy and completeness of the data and analyses.
Both the full study-entry criteria, included in the Supplementary Appendix, and the trial protocol are available with the full text of this article at NEJM.org. Briefly, patients with Wegener’s granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had positive serum assays for proteinase 3–ANCA or myeloperoxidase-ANCA, manifestations of severe disease,11 (link) and a Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease).25 (link) Patients with either newly diagnosed or relapsing disease were eligible for enrollment. The RAVE trial was approved by the institutional review board at each participating site. All patients provided written informed consent.
Patients were randomly assigned, in a 1:1 ratio, to investigational therapy (the rituximab group) or standard therapy (the control group). Randomization was stratified according to clinical site and ANCA type.
Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., Kallenberg C.G., St. Clair E.W., Turkiewicz A., Tchao N.K., Webber L., Ding L., Sejismundo L.P., Mieras K., Weitzenkamp D., Ikle D., Seyfert-Margolis V., Mueller M., Brunetta P., Allen N.B., Fervenza F.C., Geetha D., Keogh K.A., Kissin E.Y., Monach P.A., Peikert T., Stegeman C., Ytterberg S.R, & Specks U. (2010). Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. The New England journal of medicine, 363(3), 221-232.
Publication 2010
Antineutrophil Cytoplasmic Antibodies Biological Assay Clinical Investigators Committee Members Endopeptidases Ethics Committees, Research Granulomatosis with Polyangiitis Immune Tolerance Patients Peroxidase Polyangiitides, Microscopic Rituximab Serum Therapies, Investigational Vasculitis
5
Validation of Stroke Diagnosis Coding
Analyses were stratified according to event type, i.e., IS or ICH, and event position, primary or other. Validation rates were compared across the three clinical sites and across calendar years. For IS, we also assessed the accuracy of specific ICD-9 codes (433, 434, and 436). We subsequently assessed the validity of the AF diagnosis ICD-9 code (427.31) based on ECG. Final validation assessment excluded IS due to a different mechanism (i.e. strokes determined by medical record review to be attributable to vascular procedures, tumors, infection, or vasculitis) and ICH secondary to a surgical procedure or major trauma that had not been initially excluded due to lack of an accompanying ICD-9 trauma code. To further assess errors of ICD-9 coding, we also determined the accuracy of the “without infarction” modifier.
Data are displayed as counts and percentages. Bivariate analyses were performed and differences assessed with Chi-square tests for event type, event coding position, clinical site, and IS code. We calculated the positive predictive value (PPV) for each of these categories. All analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC).
Thigpen J.L., Dillon C., Forster K.B., Henault L., Quinn E.K., Tripodis Y., Berger P.B., Hylek E.M, & Limdi N.A. (2015). Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage among Individuals with Associated Diagnosis of Atrial Fibrillation: Thigpen et al: ICD-9 Stroke Case and Atrial Fibrillation Accuracy. Circulation. Cardiovascular quality and outcomes, 8(1), 8-14.
Publication 2015
Blood Vessel Cerebrovascular Accident Diagnosis Infarction Infection Neoplasms Operative Surgical Procedures Vasculitis Wounds and Injuries

Most recents protocols related to «Vasculitis»

1
Standardized Cardiovascular MRI Protocols
All cardiovascular MRI examinations were performed using a 1.5-Tesla scanner (Signa HDx; GE Medical Systems, Milwaukee, WI, USA) with a 32-channel phased-array abdominal coil with electrocardiographic gating. Intravenous sedation was not administered during the examination. All the patients were trained how to take a breath before the examination. The weight and height of the patients were recorded before the examination to calculate body surface area to index ventricular volume.
All examinations were performed by two technologists and 10 years experienced radiologist trained in congenital cardiac imaging. After three plane localizers through thorax revealed by steady-state free precession sequence, cine-steady state free precession sequence of two-chambers, four-chambers, and short-axis views (Protocol 1) was revealed for all patients. Each set of images was acquired with retrospective gating and 20 reconstructed cardiac phases. All the images were acquired during one or two breath-hold of 8 to 12 s duration depending on the heart rate during end-expiratory breath-hold.
A 0.2 mmol/kg of gadolinium-based contrast agent was performed if the imaging protocol was required. Contrast agent material was used for magnetic resonance angiography (MRA) for great vessels (Protocol 3), myocardial late gadolinium enhancement (Protocol 4), tissue characterization (Protocol 5), perfusion imaging (Perfusion 6), and vasculitis assessment (Protocol 8). Contrast-enhanced MRA was used to prescribe the phase-contrast imaging of the pulmonary artery, aorta. The optimal velocity encoding value of the pulmonary artery was calculated by the calculation Bernoulli equation reported gradients in the echocardiography report. Late gadolinium enhancement sequences were revealed after 10 and 15 min of injection for the assessment of myocardial disease.
Protocols 1–4 were applied for the patients with the indication of CHD. Protocols 1, 3, and 4 were applied for the patients with the indication of myocardial disease, and Protocols 1 and 7 were applied for myocardial iron assessment. Protocols 1, 5, and 6 were applied for the patients with the indication of cardiac mass. Protocols 1, 2, 3, and 4 were applied for valvular disease; protocols 1, 2, 3, 4, and 5 were applied for pericarditis; protocols 1 and 9 were applied for coronary artery assessment; and protocols 1 and 3 were applied for MRA of great vessels.
Our institutional standardized cardiovascular MRI protocol demonstrated with imaging parameters was performed (Table 1).
Ozkok S., Yucel I.K., Sasmazel A, & Celebi A. (2023). Experience of 500 cardiovascular magnetic resonance imaging and systematic analysis of cases. Northern Clinics of Istanbul, 10(1), 108-121.
Publication 2023
Abdomen Aorta Artery, Coronary Blood Vessel Body Surface Area Cardiomyopathies Cardiovascular System Chest Echocardiography Electrocardiography Epistropheus Exhaling Gadolinium Heart Heart Ventricle Iron Magnetic Resonance Angiography Microscopy, Phase-Contrast Myocardium Patients Perfusion Pericarditis Physical Examination Pulmonary Artery Radiologist Rate, Heart Sedatives Tissues Vasculitis
2
European Consensus on Vascular Catheter Infection Prevention

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Blood Vessel Catheters Communicable Diseases Conferences Europeans Infection Intensive Care Therapeutics Vascular Surgical Procedures Vasculitis
3
Nationwide Survey of Intracranial Carotid Dissection
This nationwide survey was conducted after obtaining authorization from the Japanese Society of Surgery for Cerebral Stroke. The study protocol was approved by the Institutional Review Board (IRB) of the Akita University Graduate School of Medicine (No. 2640). A letter of invitation to participate in this study was sent to 870 centers that served as training hospitals for the Board Certification Program of the Japanese Neurosurgical Society. Overall, 35 neurosurgical centers reported relevant cases and participated in this retrospective study after the approval of the IRBs of each center. The requirement for informed written consent from the included patients was waived because of the retrospective and noninvasive nature of this study.
The inclusion criteria were the following: (i) first-ever patients with IsICD admitted between January 2015 and December 2020 and (ii) within 2 weeks after ischemic onset due to IsICD lesions. No age or sex restrictions were imposed. Furthermore, no exclusion criteria were established.
In this study, IsICD was defined to represent spontaneous intracranial and intradural carotid dissections distal to the ophthalmic artery. Carotid dissections determined to originate from the cavernous, petrous, or cervical portion and possibly caused by trauma, vasculitis, or iatrogenic procedures were not regarded as the IsICD in this study. At least one of the following findings was required on magnetic resonance angiography (MRA), computed tomography angiography, or conventional angiography: double lumen, pearl and string sign, intimal flap, tapering stenosis or occlusion, and intramural hematoma.10 ,17 )
SHIMIZU H., ONO T., ABE T., HOKARI M., EGASHIRA Y., SHIMONAGA K., KAWANISHI M., NOMURA K, & TAKAHASHI Y. (2023). Current Treatment Results of Intracranial Carotid Artery Dissection Causing Cerebral Ischemia: A Japanese Nationwide Survey. Neurologia medico-chirurgica, 63(2), 80-89.
Publication 2023
Angiography Carotid Arteries Cerebrovascular Accident Computed Tomography Angiography Dental Occlusion Dissection Ethics Committees, Research Hematoma Japanese Magnetic Resonance Angiography Neck Operative Surgical Procedures Ophthalmic Artery Patients Pharmaceutical Preparations Stenosis Surgical Flaps Tunica Intima Vasculitis Wounds and Injuries
4
Cost-Effectiveness of DMARD Regimens in Rheumatoid Arthritis
This prospective observational study was carried out in the Department of Pharmacology in a tertiary care institute over a period of one year after approval from the Institutional Ethics Committee (All India Institute of Medical Sciences (AIIMS), Rishikesh) (approval number AIIMS/IEC/18/160). Our study followed the principles of the Declaration of Helsinki. Subjects were recruited from patients presenting to the Rheumatology Outpatient Department (OPD) with a primary diagnosis of RA after obtaining written informed consent. Inclusion criteria were all new and previously diagnosed patients with rheumatoid arthritis based on the American College of Rheumatology (ACR) 2010 diagnostic criteria of either sex. Patients excluded from this study included those affected with arthritis due to reasons other than RA, such as vasculitis, polymyalgia rheumatica, spondyloarthropathies (reactive arthritis, ankylosing spondylitis, and psoriatic arthritis), bacterial arthritis, and fibromyalgia.
On the basis of DMARD therapy being received by the patients, they were divided into different groups: Regimen 1, monotherapy with one DMARD (methotrexate (MTX)); Regimen 2, double DMARD therapy or two DMARD therapy (methotrexate + hydroxychloroquine (MTX + HCQ)); Regimen 3, triple DMARD therapy or three DMARD therapy (methotrexate + hydroxychloroquine + leflunomide (MTX + HCQ + Lef)); and Regimen 4, >3 DMARD therapy (MTX + HCQ + Lef + bDMARD adalimumab). Patients were assessed at baseline and after the follow-up visit as per the clinician’s discretion (varying from 7 to 12 weeks). Treatment response was recorded at the baseline and follow-up visit based on the Disease Activity Score (DAS28) criteria, which comprises a number of tender joints, swollen joints, erythrocyte sedimentation rate (ESR), and “patient global health” score [10 (link)].
The medication cost of DMARD therapy was analyzed by calculating the cost of therapy per month for each patient by taking the prices from the Bureau of Pharma Public Sector Undertakings of India (BPPI), Department of Pharmaceuticals, Government of India, for all the DMARDs, except the biological drug for which the price from Cadila Healthcare Ltd. (Zydus Cadila, Ahmedabad, India) was taken. Cost-effectiveness was calculated by dividing the cost of therapy by the change in DAS in a month. Adherence was assessed using the Morisky-Green-Levine Scale (MGLS) [11 (link)]. Patients were interviewed and asked to answer four questions listed in the questionnaire on their second visit. High adherence was denoted by a score of 0, medium adherence was denoted by a score of 1 or 2, and low adherence was denoted by a score of 3 or 4. The p value was taken to be 0.05. For the cost-effective analysis, the mean was applied to the DAS28 values and the cost of treatment. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software (IBM SPSS Statistics, Armonk, NY, USA).
Mittal G., Bisht M., Pai V.S, & Handu S. (2023). The Cost-Effectiveness of and Adherence to Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis Patients in a Tertiary Care Teaching Hospital in Uttarakhand, India. Cureus, 15(2), e34664.
Full text: Click here
Publication 2023
Adalimumab Ankylosing Spondylitis Antirheumatic Drugs, Disease-Modifying Arthritis Arthritis, Bacterial Arthritis, Psoriatic Arthritis, Reactive Biopharmaceuticals Diagnosis Fibromyalgia Institutional Ethics Committees Joints Leflunomide Methotrexate Outpatients Patients Pharmaceutical Preparations Pharmacotherapy Polymyalgia Rheumatica Public Sector Rheumatoid Arthritis Sedimentation Rates, Erythrocyte Spondylarthropathies Therapeutics Treatment Protocols Vasculitis
5
Evaluating Impact of ASP on MDRO
The primary outcome of the study was to evaluate the impact of the implementation of an ASP in the Vascular Surgery ward on the occurrence of MDRO infections.
Secondary outcomes included changes before, during and after the implementation of the ASP in terms of number of admissions in the Vascular Surgery ward for at least 48 h, length of stay (LOS), all-cause in-hospital mortality rate, antimicrobial consumption, and costs.
Vecchia M., Colaneri M., Sacchi P., Marvulli L.N., Salvaderi A., Lanza J., Boschini S., Ragni F., Marone P., Cutti S., Muzzi A., Marena C., Calvi M., Scudeller L., Marone E.M, & Bruno R. (2023). Implementation of an antimicrobial stewardship program in the Vascular Surgery ward of a university tertiary care hospital in Pavia, Northern Italy. BMC Infectious Diseases, 23, 138.
Full text: Click here
Publication 2023
Microbicides Operative Surgical Procedures Vascular Surgical Procedures Vasculitis

Top products related to «Vasculitis»

1
Akta fplc system by GE Healthcare
Sourced in United States, United Kingdom, Sweden, Germany, Italy, Canada
The AKTA FPLC system is a versatile and high-performance liquid chromatography instrument designed for protein purification and analysis. It offers precise control and monitoring of key parameters, such as flow rate, pressure, and UV absorbance, to ensure efficient and reliable separation of biomolecules.
2
Bx43 microscope by Olympus
Sourced in Japan, United States, Germany, China, United Kingdom, Spain
The Olympus BX43 is a high-performance optical microscope designed for a wide range of applications. It features a sturdy and durable construction, with a built-in illumination system and a range of objective lenses to accommodate various magnification requirements. The BX43 is equipped with a sturdy, ergonomic design that promotes comfortable operation during extended use.
3
Pierce coomassie protein assay kit by Thermo Fisher Scientific
Sourced in United States
The Pierce Coomassie Protein Assay Kit is a colorimetric assay designed to quantify total protein concentration. The kit utilizes Coomassie dye-binding technology to provide a simple, rapid, and sensitive method for measuring protein levels in solution.
4
Surgical microscope by Zeiss
Sourced in Germany
The Zeiss Surgical Microscope is a precision optical instrument designed for use in delicate surgical procedures. It provides a magnified and illuminated view of the surgical site, enabling surgeons to perform intricate operations with enhanced visibility and accuracy.
5
Stata software by StataCorp
Sourced in United States, United Kingdom, Denmark, Austria
Stata is a general-purpose statistical software package for data analysis, data management, and graphics. It provides a wide range of data manipulation, statistical, and graphical tools to help researchers and analysts effectively analyze and visualize data.
6
Prism 9 by GraphPad
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
7
Elisa kit by Thermo Fisher Scientific
Sourced in United States, Austria, United Kingdom, China, Germany, Italy, Belgium, Canada, France, Brazil, Australia, India, Spain, Israel, Pakistan, Ireland
ELISA (Enzyme-Linked Immunosorbent Assay) kits are a set of laboratory equipment and reagents used to detect and quantify specific proteins, hormones, or other analytes in a sample. The kits utilize the principles of immunoassay technology, where antibodies are used to capture and detect the target analyte. The core function of ELISA kits is to provide a standardized and sensitive method for the quantitative analysis of these analytes in various biological samples.
8
Elisa kit by EUROIMMUN
Sourced in Germany, Poland
The ELISA kit is a laboratory equipment designed for the detection and quantification of specific analytes in a sample. It utilizes an enzyme-linked immunosorbent assay (ELISA) technique to measure the presence and concentration of target molecules. The kit provides the necessary reagents and procedures to perform this analytical method.
9
Evans blue by Merck Group
Sourced in United States, Germany, Sao Tome and Principe, China, United Kingdom, Macao, Spain, Japan, Ireland, Italy
Evans blue is a dye used as a laboratory reagent. It is a blue-colored dye that binds to albumin in the blood, allowing for the measurement and visualization of blood volume and albumin distribution. The dye has a strong blue color and is soluble in water.
10
High trap protein g column by GE Healthcare
Sourced in United States
The High-Trap-protein G column is a chromatography column designed for the purification of antibodies. It utilizes a protein G ligand, which has a high affinity for the Fc region of immunoglobulins, to selectively capture and separate antibodies from complex mixtures. The column offers efficient and reliable antibody purification.

More about "Vasculitis"

vascular inflammation, vessel wall damage, autoimmune vasculopathy, infectious vasculitis, organ dysfunction, fever, fatigue, pain, AKTA FPLC, BX43 microscope, Pierce Coomassie Protein Assay Kit, surgical microscope, Stata software, Prism 9, ELISA kits, Evans blue, High-Trap-protein G column, PubCompare.ai, research protocols, published literature, preprints, patents